Obesity-focused biotech BioAge Labs said on Wednesday it was seeking a valuation of as much as $587 million in its initial public offering in the United States, according to a regulatory filing.

The device is a variant of Neuralink's brain implant technology, in this case designed to "enable even those who have lost both eyes" to see, according to owner Elon Musk. Separately, progress is ...

Eli Lilly stock may look expensive, but that may not be the case in a few years as the business grows at a rapid pace.

Eli Lilly’s stock has climbed almost 60% this year and trades for more than $900. The pharma giant also has seen soaring ...

A phenomenon called 'Ozempic Babies' are raising concerns about weight loss drugs after multiple reports of surprise ...

Ozempic, Wegovy, Zepbound, and Mounjaro are but a few of the injectable drugs that are currently revolutionizing the size of ...

Wegovy, Zepbound and other cutting-edge weight-loss drugs can be tough to get these days. They’re in short supply, and often ...

Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Glucagon-like peptide 1 (GLP-1) receptor agonists like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound), ...

Most U.S. patients are covered by health insurance and would likely pay less for the drugs. Novo and rival Eli Lilly, which makes the weight loss drug Zepbound, have filed a flurry of lawsuits against ...

The S&P 500 ended 0.3% lower on Wednesday, Sept. 18, 2024, as the Federal Reserve announced its first interest-rate cut since ...

There is soaring demand for weight-loss drugs in the GLP-1 class, and the company will now sell it to certain professions for ...

Obesity-focused biotech BioAge Labs said on Wednesday it was seeking a valuation of as much as $587 million in its initial public offering in the United States, according to a regulatory filing.